Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Silverman

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Pharmacology in Drug Development|August 10, 2018
Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy VolunteersHua Yang, Elizabeth Merica, Yue Chen, et al.
Human Molecular Genetics|April 8, 2016
A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2Barden Chan, Michelle Clasquin, Gromoslaw A Smolen, et al.
Blood|August 2, 2017
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiencyCharles Kung, Jeff Hixon, Penelope A Kosinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2011
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assaysMark G Manfredi, Jeffrey A Ecsedy, Arijit Chakravarty, et al.
Science (New York, N.Y.)|April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsDan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Cancer Research|December 15, 2010
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinaseArijit Chakravarty, Vaishali Shinde, Josep Tabernero, et al.
Journal of Inherited Metabolic Disease|July 30, 2016
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse modelFang Wang, Jeremy Travins, Zhizhong Lin, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Pharmacology in Drug Development|August 10, 2018
Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy VolunteersHua Yang, Elizabeth Merica, Yue Chen, et al.
Human Molecular Genetics|April 8, 2016
A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2Barden Chan, Michelle Clasquin, Gromoslaw A Smolen, et al.
Blood|August 2, 2017
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiencyCharles Kung, Jeff Hixon, Penelope A Kosinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2011
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assaysMark G Manfredi, Jeffrey A Ecsedy, Arijit Chakravarty, et al.
Science (New York, N.Y.)|April 6, 2013
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsDan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, et al.
Cancer Research|December 15, 2010
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinaseArijit Chakravarty, Vaishali Shinde, Josep Tabernero, et al.
Journal of Inherited Metabolic Disease|July 30, 2016
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse modelFang Wang, Jeremy Travins, Zhizhong Lin, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
Pageof 2